Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring.
about
Imiglucerase in the treatment of Gaucher disease: a history and perspectiveEliglustat tartrate for the treatment of adults with type 1 Gaucher diseaseUnderstanding the natural history of Gaucher diseaseA Review of Gaucher Disease Pathophysiology, Clinical Presentation and TreatmentsMandibular and dental manifestations of Gaucher disease.Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4-5 years.Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatmentOutcome of pregnancies in women receiving velaglucerase alfa for Gaucher disease.Hemorrhagic aspects of Gaucher disease.Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher diseaseDiagnosis features of pediatric Gaucher disease patients in the era of enzymatic therapy, a national-base study from the Spanish Registry of Gaucher Disease.Expanding spectrum of the association between Type 1 Gaucher disease and cancers: a series of patients with up to 3 sequential cancers of multiple types--correlation with genotype and phenotype.The European Gaucher Alliance: a survey of member patient organisations' activities, healthcare environments and concerns.ELIGLUSTAT TARTRATE: Glucosylceramide Synthase Inhibitor Treatment of Type 1 Gaucher Disease.Gaucher disease and its treatment options.Gaucher disease: clinical profile and therapeutic developments.Liver fibrosis in type I Gaucher disease: magnetic resonance imaging, transient elastography and parameters of iron storageA reappraisal of Gaucher disease-diagnosis and disease management algorithms.Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies.Replacement Therapy for Gaucher Disease during Pregnancy: A Case Report.Reducing selection bias in case-control studies from rare disease registries.Evaluation of disease burden and response to treatment in adults with type 1 Gaucher disease using a validated disease severity scoring system (DS3)Improvement in Bone Mineral Density and Architecture in a Patient with Gaucher Disease Using Teriparatide.Magnetic resonance imaging and BMB score in the evaluation of bone involvement in Gaucher's disease patientsBone turnover markers in patients with type 1 Gaucher disease.Pulmonary vascular disease in Gaucher disease: clinical spectrum, determinants of phenotype and long-term outcomes of therapy.Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis.Glucocerebroside: an evolutionary advantage for patients with Gaucher disease and a new immunomodulatory agent.Decreased bone formation and increased osteoclastogenesis cause bone loss in mucolipidosis II.Enzyme therapy for the treatment of type 1 Gaucher disease: clinical outcomes and dose - response relationships.Gaucher disease: the metabolic defect, pathophysiology, phenotypes and natural history.The history and accomplishments of the ICGG Gaucher registry.Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry.Gaucher disease: resetting the clinical and scientific agenda.The expanding role of genetics in the lewy body diseases: the glucocerebrosidase gene.Alpha versus beta: are we on the way to resolve the mystery as to which is the endogenous ligand for natural killer T cells?Letter to the Editor on "Enzyme Replacement or Substrate Reduction? A Review of Gaucher Disease Treatment Options".Medical Management of Pulmonary Hypertension with Unclear and/or Multifactorial Mechanisms (Group 5): Is There a Role for Pulmonary Arterial Hypertension Medications?Enzyme replacement therapy for Gaucher disease in twin pregnancy
P2860
Q24631426-72434B28-459F-4F2F-9205-5AEA388834A0Q26783393-58FF17FA-A89A-44B2-A598-ADA220C7BEF7Q26865974-769C1ACA-D856-4B3F-888B-B98F56965C7CQ30235844-15C30A47-E5EA-4F45-BDE2-9BE9DFD1C171Q33399221-CA61F38D-67C6-49E2-8993-111D1716CB97Q33401459-375AF124-67E1-4D7D-8B7A-6DD8B644638EQ33403298-F6AA2DD0-8FB5-476F-8D78-1384CAD6C951Q33413797-BD50D96F-5335-4007-A6FB-EB6C5BFC2496Q33418647-F20F93AB-88F5-4427-A071-79D402FED0FEQ33478327-FB019A3E-B9C4-4BA9-87F3-1EDE88B70C49Q33634529-7A769942-451A-4635-A9FB-A74D87F053E5Q33874873-6C51D57B-4D54-4ECA-84FB-C7A48E968E35Q34151422-BFA5F4DB-5110-4D27-B2E2-9E0A93A90C5CQ34273177-B3AD807B-A0CF-4C4E-868F-9224F4603228Q34386658-3781931E-AB0F-47C4-95FC-9A483F87EDB4Q34443517-A37F0700-A2F0-4E59-B1B3-71A202F03FF2Q34647861-BB06445F-19B0-43CF-8E88-CA68B68F62CCQ34683786-28764909-087E-4B1D-86B1-2C9A032EEE94Q35028532-5441B70A-20A2-473D-A1CD-E08B3D76AF4DQ35065242-46E78A25-917F-4089-9C88-8291FE61A883Q35439561-CEC81750-608E-475A-9082-25EEE73298E1Q35754621-D1B2C5B4-26CD-4838-BE5D-95FE125A943FQ35801017-DAD6536A-13CD-4AE1-81D5-816DD5C24BC0Q36052558-E24161CC-F0C8-4C71-8102-7FA0405D5915Q36562916-128AD40F-EFC4-423C-85E4-CE6E10D717D1Q37195824-9D2294F1-09FA-439A-9E79-916A11DB7C0FQ37413920-B23BADBD-1755-4B40-8988-9A5B2E65718BQ37520646-1037C7C0-BBE4-4577-A0E0-60CCE16BE939Q37557163-1776747A-9494-433F-9D4C-5427486C8599Q37594794-9077EC65-FE47-45DD-9EF1-D683C9040A13Q38262722-BC5DFABA-F9F7-4509-B98F-6A2E94E7C28FQ41652308-49203690-0706-4BB3-97ED-C75D49D9517AQ41901693-F79FABCA-756A-43E0-8899-E80AA1ED4DCEQ42331780-BEC56BAB-287E-4983-9186-F04407D4DFF2Q42585265-1C72DF6D-6BE1-4968-9614-4D0D8BD5B13BQ43759628-3ADAAA9B-3104-41FB-A0B2-B35A38159936Q49587267-7D394F67-4A0A-4C5F-BCF6-695002A2C61AQ50092007-396DC175-4070-4DD1-B926-93C8AAFE97E8Q57847694-1426021D-70FE-41F4-97FF-4FBD0BDA5056
P2860
Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Management of non-neuronopathi ...... s and bone disease monitoring.
@en
Management of non-neuronopathi ...... s and bone disease monitoring.
@nl
type
label
Management of non-neuronopathi ...... s and bone disease monitoring.
@en
Management of non-neuronopathi ...... s and bone disease monitoring.
@nl
prefLabel
Management of non-neuronopathi ...... s and bone disease monitoring.
@en
Management of non-neuronopathi ...... s and bone disease monitoring.
@nl
P2093
P2860
P1476
Management of non-neuronopathi ...... s and bone disease monitoring.
@en
P2093
A M Martins
C E M Hollak
G A Grabowski
G M Pastores
J Goldblatt
J M F G Aerts
M D Cappellini
N Belmatoug
P2860
P2888
P304
P356
10.1007/S10545-008-0779-Z
P577
2008-05-23T00:00:00Z